0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Anti-VEGF Therapy for Cancer Market Research Report 2024
Published Date: August 2024
|
Report Code: QYRE-Auto-2Y18155
Home | Market Reports | Health| Health Conditions| Cancer
Global Anti VEGF Therapy for Cancer Market Research Report 2024
BUY CHAPTERS

Global Anti-VEGF Therapy for Cancer Market Research Report 2024

Code: QYRE-Auto-2Y18155
Report
August 2024
Pages:90
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Anti-VEGF Therapy for Cancer Market

Anti-VEGF Therapy for Cancer involves using drugs that inhibit vascular endothelial growth factor(VEGF),a protein crucial for blood vessel formation.By blockingVEGFor its receptors,these therapies aim to disrupt the formation of new blood vessels that tumors need to grow and metastasize.This approach helps to slow down or stop the progression of various cancers,such as colorectal,lung,and renal cell carcinoma.
The global Anti-VEGF Therapy for Cancer market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Anti-VEGF Therapy for Cancer is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Anti-VEGF Therapy for Cancer is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Anti-VEGF Therapy for Cancer in Colorectal Cancer is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Anti-VEGF Therapy for Cancer include Sanofi, Eli Lilly, Roche, Bayer, Pfizer, Jiangsu Hengrui Pharmaceuticals, Chia Tai Tianqing, Novartis, AstraZeneca, Exelixis, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Anti-VEGF Therapy for Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-VEGF Therapy for Cancer.
The Anti-VEGF Therapy for Cancer market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Anti-VEGF Therapy for Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anti-VEGF Therapy for Cancer companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Anti-VEGF Therapy for Cancer Market Report

Report Metric Details
Report Name Anti-VEGF Therapy for Cancer Market
Segment by Type
Segment by Application
  • Colorectal Cancer
  • Non-small Cell Lung Cancer
  • Renal Cell Carcinoma
  • Cervical Cancer
  • Medullary Thyroid Cancer
  • Other
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Sanofi, Eli Lilly, Roche, Bayer, Pfizer, Jiangsu Hengrui Pharmaceuticals, Chia Tai Tianqing, Novartis, AstraZeneca, Exelixis, Boehringer Ingelheim, Eisai, Janssen Biotech
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Anti-VEGF Therapy for Cancer company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Anti-VEGF Therapy for Cancer Market report?

Ans: The main players in the Anti-VEGF Therapy for Cancer Market are Sanofi, Eli Lilly, Roche, Bayer, Pfizer, Jiangsu Hengrui Pharmaceuticals, Chia Tai Tianqing, Novartis, AstraZeneca, Exelixis, Boehringer Ingelheim, Eisai, Janssen Biotech

What are the Application segmentation covered in the Anti-VEGF Therapy for Cancer Market report?

Ans: The Applications covered in the Anti-VEGF Therapy for Cancer Market report are Colorectal Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Cervical Cancer, Medullary Thyroid Cancer, Other

What are the Type segmentation covered in the Anti-VEGF Therapy for Cancer Market report?

Ans: The Types covered in the Anti-VEGF Therapy for Cancer Market report are VEGF Inhibitors, VEGFR Inhibitors

Recommended Reports

Anti-VEGF Markets

Cancer Therapeutics

Targeted Inhibitors

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Anti-VEGF Therapy for Cancer Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 VEGF Inhibitors
1.2.3 VEGFR Inhibitors
1.3 Market by Application
1.3.1 Global Anti-VEGF Therapy for Cancer Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Colorectal Cancer
1.3.3 Non-small Cell Lung Cancer
1.3.4 Renal Cell Carcinoma
1.3.5 Cervical Cancer
1.3.6 Medullary Thyroid Cancer
1.3.7 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Anti-VEGF Therapy for Cancer Market Perspective (2019-2030)
2.2 Global Anti-VEGF Therapy for Cancer Growth Trends by Region
2.2.1 Global Anti-VEGF Therapy for Cancer Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Anti-VEGF Therapy for Cancer Historic Market Size by Region (2019-2024)
2.2.3 Anti-VEGF Therapy for Cancer Forecasted Market Size by Region (2025-2030)
2.3 Anti-VEGF Therapy for Cancer Market Dynamics
2.3.1 Anti-VEGF Therapy for Cancer Industry Trends
2.3.2 Anti-VEGF Therapy for Cancer Market Drivers
2.3.3 Anti-VEGF Therapy for Cancer Market Challenges
2.3.4 Anti-VEGF Therapy for Cancer Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Anti-VEGF Therapy for Cancer Players by Revenue
3.1.1 Global Top Anti-VEGF Therapy for Cancer Players by Revenue (2019-2024)
3.1.2 Global Anti-VEGF Therapy for Cancer Revenue Market Share by Players (2019-2024)
3.2 Global Anti-VEGF Therapy for Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Anti-VEGF Therapy for Cancer Revenue
3.4 Global Anti-VEGF Therapy for Cancer Market Concentration Ratio
3.4.1 Global Anti-VEGF Therapy for Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Anti-VEGF Therapy for Cancer Revenue in 2023
3.5 Global Key Players of Anti-VEGF Therapy for Cancer Head office and Area Served
3.6 Global Key Players of Anti-VEGF Therapy for Cancer, Product and Application
3.7 Global Key Players of Anti-VEGF Therapy for Cancer, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Anti-VEGF Therapy for Cancer Breakdown Data by Type
4.1 Global Anti-VEGF Therapy for Cancer Historic Market Size by Type (2019-2024)
4.2 Global Anti-VEGF Therapy for Cancer Forecasted Market Size by Type (2025-2030)
5 Anti-VEGF Therapy for Cancer Breakdown Data by Application
5.1 Global Anti-VEGF Therapy for Cancer Historic Market Size by Application (2019-2024)
5.2 Global Anti-VEGF Therapy for Cancer Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Anti-VEGF Therapy for Cancer Market Size (2019-2030)
6.2 North America Anti-VEGF Therapy for Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Anti-VEGF Therapy for Cancer Market Size by Country (2019-2024)
6.4 North America Anti-VEGF Therapy for Cancer Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Anti-VEGF Therapy for Cancer Market Size (2019-2030)
7.2 Europe Anti-VEGF Therapy for Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Anti-VEGF Therapy for Cancer Market Size by Country (2019-2024)
7.4 Europe Anti-VEGF Therapy for Cancer Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Anti-VEGF Therapy for Cancer Market Size (2019-2030)
8.2 Asia-Pacific Anti-VEGF Therapy for Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Anti-VEGF Therapy for Cancer Market Size by Region (2019-2024)
8.4 Asia-Pacific Anti-VEGF Therapy for Cancer Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Anti-VEGF Therapy for Cancer Market Size (2019-2030)
9.2 Latin America Anti-VEGF Therapy for Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Anti-VEGF Therapy for Cancer Market Size by Country (2019-2024)
9.4 Latin America Anti-VEGF Therapy for Cancer Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Anti-VEGF Therapy for Cancer Market Size (2019-2030)
10.2 Middle East & Africa Anti-VEGF Therapy for Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Anti-VEGF Therapy for Cancer Market Size by Country (2019-2024)
10.4 Middle East & Africa Anti-VEGF Therapy for Cancer Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Details
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Anti-VEGF Therapy for Cancer Introduction
11.1.4 Sanofi Revenue in Anti-VEGF Therapy for Cancer Business (2019-2024)
11.1.5 Sanofi Recent Development
11.2 Eli Lilly
11.2.1 Eli Lilly Company Details
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly Anti-VEGF Therapy for Cancer Introduction
11.2.4 Eli Lilly Revenue in Anti-VEGF Therapy for Cancer Business (2019-2024)
11.2.5 Eli Lilly Recent Development
11.3 Roche
11.3.1 Roche Company Details
11.3.2 Roche Business Overview
11.3.3 Roche Anti-VEGF Therapy for Cancer Introduction
11.3.4 Roche Revenue in Anti-VEGF Therapy for Cancer Business (2019-2024)
11.3.5 Roche Recent Development
11.4 Bayer
11.4.1 Bayer Company Details
11.4.2 Bayer Business Overview
11.4.3 Bayer Anti-VEGF Therapy for Cancer Introduction
11.4.4 Bayer Revenue in Anti-VEGF Therapy for Cancer Business (2019-2024)
11.4.5 Bayer Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Details
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Anti-VEGF Therapy for Cancer Introduction
11.5.4 Pfizer Revenue in Anti-VEGF Therapy for Cancer Business (2019-2024)
11.5.5 Pfizer Recent Development
11.6 Jiangsu Hengrui Pharmaceuticals
11.6.1 Jiangsu Hengrui Pharmaceuticals Company Details
11.6.2 Jiangsu Hengrui Pharmaceuticals Business Overview
11.6.3 Jiangsu Hengrui Pharmaceuticals Anti-VEGF Therapy for Cancer Introduction
11.6.4 Jiangsu Hengrui Pharmaceuticals Revenue in Anti-VEGF Therapy for Cancer Business (2019-2024)
11.6.5 Jiangsu Hengrui Pharmaceuticals Recent Development
11.7 Chia Tai Tianqing
11.7.1 Chia Tai Tianqing Company Details
11.7.2 Chia Tai Tianqing Business Overview
11.7.3 Chia Tai Tianqing Anti-VEGF Therapy for Cancer Introduction
11.7.4 Chia Tai Tianqing Revenue in Anti-VEGF Therapy for Cancer Business (2019-2024)
11.7.5 Chia Tai Tianqing Recent Development
11.8 Novartis
11.8.1 Novartis Company Details
11.8.2 Novartis Business Overview
11.8.3 Novartis Anti-VEGF Therapy for Cancer Introduction
11.8.4 Novartis Revenue in Anti-VEGF Therapy for Cancer Business (2019-2024)
11.8.5 Novartis Recent Development
11.9 AstraZeneca
11.9.1 AstraZeneca Company Details
11.9.2 AstraZeneca Business Overview
11.9.3 AstraZeneca Anti-VEGF Therapy for Cancer Introduction
11.9.4 AstraZeneca Revenue in Anti-VEGF Therapy for Cancer Business (2019-2024)
11.9.5 AstraZeneca Recent Development
11.10 Exelixis
11.10.1 Exelixis Company Details
11.10.2 Exelixis Business Overview
11.10.3 Exelixis Anti-VEGF Therapy for Cancer Introduction
11.10.4 Exelixis Revenue in Anti-VEGF Therapy for Cancer Business (2019-2024)
11.10.5 Exelixis Recent Development
11.11 Boehringer Ingelheim
11.11.1 Boehringer Ingelheim Company Details
11.11.2 Boehringer Ingelheim Business Overview
11.11.3 Boehringer Ingelheim Anti-VEGF Therapy for Cancer Introduction
11.11.4 Boehringer Ingelheim Revenue in Anti-VEGF Therapy for Cancer Business (2019-2024)
11.11.5 Boehringer Ingelheim Recent Development
11.12 Eisai
11.12.1 Eisai Company Details
11.12.2 Eisai Business Overview
11.12.3 Eisai Anti-VEGF Therapy for Cancer Introduction
11.12.4 Eisai Revenue in Anti-VEGF Therapy for Cancer Business (2019-2024)
11.12.5 Eisai Recent Development
11.13 Janssen Biotech
11.13.1 Janssen Biotech Company Details
11.13.2 Janssen Biotech Business Overview
11.13.3 Janssen Biotech Anti-VEGF Therapy for Cancer Introduction
11.13.4 Janssen Biotech Revenue in Anti-VEGF Therapy for Cancer Business (2019-2024)
11.13.5 Janssen Biotech Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
 Table 1. Global Anti-VEGF Therapy for Cancer Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
 Table 2. Key Players of VEGF Inhibitors
 Table 3. Key Players of VEGFR Inhibitors
 Table 4. Global Anti-VEGF Therapy for Cancer Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
 Table 5. Global Anti-VEGF Therapy for Cancer Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Table 6. Global Anti-VEGF Therapy for Cancer Market Size by Region (2019-2024) & (US$ Million)
 Table 7. Global Anti-VEGF Therapy for Cancer Market Share by Region (2019-2024)
 Table 8. Global Anti-VEGF Therapy for Cancer Forecasted Market Size by Region (2025-2030) & (US$ Million)
 Table 9. Global Anti-VEGF Therapy for Cancer Market Share by Region (2025-2030)
 Table 10. Anti-VEGF Therapy for Cancer Market Trends
 Table 11. Anti-VEGF Therapy for Cancer Market Drivers
 Table 12. Anti-VEGF Therapy for Cancer Market Challenges
 Table 13. Anti-VEGF Therapy for Cancer Market Restraints
 Table 14. Global Anti-VEGF Therapy for Cancer Revenue by Players (2019-2024) & (US$ Million)
 Table 15. Global Anti-VEGF Therapy for Cancer Market Share by Players (2019-2024)
 Table 16. Global Top Anti-VEGF Therapy for Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-VEGF Therapy for Cancer as of 2023)
 Table 17. Ranking of Global Top Anti-VEGF Therapy for Cancer Companies by Revenue (US$ Million) in 2023
 Table 18. Global 5 Largest Players Market Share by Anti-VEGF Therapy for Cancer Revenue (CR5 and HHI) & (2019-2024)
 Table 19. Global Key Players of Anti-VEGF Therapy for Cancer, Headquarters and Area Served
 Table 20. Global Key Players of Anti-VEGF Therapy for Cancer, Product and Application
 Table 21. Global Key Players of Anti-VEGF Therapy for Cancer, Date of Enter into This Industry
 Table 22. Mergers & Acquisitions, Expansion Plans
 Table 23. Global Anti-VEGF Therapy for Cancer Market Size by Type (2019-2024) & (US$ Million)
 Table 24. Global Anti-VEGF Therapy for Cancer Revenue Market Share by Type (2019-2024)
 Table 25. Global Anti-VEGF Therapy for Cancer Forecasted Market Size by Type (2025-2030) & (US$ Million)
 Table 26. Global Anti-VEGF Therapy for Cancer Revenue Market Share by Type (2025-2030)
 Table 27. Global Anti-VEGF Therapy for Cancer Market Size by Application (2019-2024) & (US$ Million)
 Table 28. Global Anti-VEGF Therapy for Cancer Revenue Market Share by Application (2019-2024)
 Table 29. Global Anti-VEGF Therapy for Cancer Forecasted Market Size by Application (2025-2030) & (US$ Million)
 Table 30. Global Anti-VEGF Therapy for Cancer Revenue Market Share by Application (2025-2030)
 Table 31. North America Anti-VEGF Therapy for Cancer Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
 Table 32. North America Anti-VEGF Therapy for Cancer Market Size by Country (2019-2024) & (US$ Million)
 Table 33. North America Anti-VEGF Therapy for Cancer Market Size by Country (2025-2030) & (US$ Million)
 Table 34. Europe Anti-VEGF Therapy for Cancer Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
 Table 35. Europe Anti-VEGF Therapy for Cancer Market Size by Country (2019-2024) & (US$ Million)
 Table 36. Europe Anti-VEGF Therapy for Cancer Market Size by Country (2025-2030) & (US$ Million)
 Table 37. Asia-Pacific Anti-VEGF Therapy for Cancer Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
 Table 38. Asia-Pacific Anti-VEGF Therapy for Cancer Market Size by Region (2019-2024) & (US$ Million)
 Table 39. Asia-Pacific Anti-VEGF Therapy for Cancer Market Size by Region (2025-2030) & (US$ Million)
 Table 40. Latin America Anti-VEGF Therapy for Cancer Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
 Table 41. Latin America Anti-VEGF Therapy for Cancer Market Size by Country (2019-2024) & (US$ Million)
 Table 42. Latin America Anti-VEGF Therapy for Cancer Market Size by Country (2025-2030) & (US$ Million)
 Table 43. Middle East & Africa Anti-VEGF Therapy for Cancer Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
 Table 44. Middle East & Africa Anti-VEGF Therapy for Cancer Market Size by Country (2019-2024) & (US$ Million)
 Table 45. Middle East & Africa Anti-VEGF Therapy for Cancer Market Size by Country (2025-2030) & (US$ Million)
 Table 46. Sanofi Company Details
 Table 47. Sanofi Business Overview
 Table 48. Sanofi Anti-VEGF Therapy for Cancer Product
 Table 49. Sanofi Revenue in Anti-VEGF Therapy for Cancer Business (2019-2024) & (US$ Million)
 Table 50. Sanofi Recent Development
 Table 51. Eli Lilly Company Details
 Table 52. Eli Lilly Business Overview
 Table 53. Eli Lilly Anti-VEGF Therapy for Cancer Product
 Table 54. Eli Lilly Revenue in Anti-VEGF Therapy for Cancer Business (2019-2024) & (US$ Million)
 Table 55. Eli Lilly Recent Development
 Table 56. Roche Company Details
 Table 57. Roche Business Overview
 Table 58. Roche Anti-VEGF Therapy for Cancer Product
 Table 59. Roche Revenue in Anti-VEGF Therapy for Cancer Business (2019-2024) & (US$ Million)
 Table 60. Roche Recent Development
 Table 61. Bayer Company Details
 Table 62. Bayer Business Overview
 Table 63. Bayer Anti-VEGF Therapy for Cancer Product
 Table 64. Bayer Revenue in Anti-VEGF Therapy for Cancer Business (2019-2024) & (US$ Million)
 Table 65. Bayer Recent Development
 Table 66. Pfizer Company Details
 Table 67. Pfizer Business Overview
 Table 68. Pfizer Anti-VEGF Therapy for Cancer Product
 Table 69. Pfizer Revenue in Anti-VEGF Therapy for Cancer Business (2019-2024) & (US$ Million)
 Table 70. Pfizer Recent Development
 Table 71. Jiangsu Hengrui Pharmaceuticals Company Details
 Table 72. Jiangsu Hengrui Pharmaceuticals Business Overview
 Table 73. Jiangsu Hengrui Pharmaceuticals Anti-VEGF Therapy for Cancer Product
 Table 74. Jiangsu Hengrui Pharmaceuticals Revenue in Anti-VEGF Therapy for Cancer Business (2019-2024) & (US$ Million)
 Table 75. Jiangsu Hengrui Pharmaceuticals Recent Development
 Table 76. Chia Tai Tianqing Company Details
 Table 77. Chia Tai Tianqing Business Overview
 Table 78. Chia Tai Tianqing Anti-VEGF Therapy for Cancer Product
 Table 79. Chia Tai Tianqing Revenue in Anti-VEGF Therapy for Cancer Business (2019-2024) & (US$ Million)
 Table 80. Chia Tai Tianqing Recent Development
 Table 81. Novartis Company Details
 Table 82. Novartis Business Overview
 Table 83. Novartis Anti-VEGF Therapy for Cancer Product
 Table 84. Novartis Revenue in Anti-VEGF Therapy for Cancer Business (2019-2024) & (US$ Million)
 Table 85. Novartis Recent Development
 Table 86. AstraZeneca Company Details
 Table 87. AstraZeneca Business Overview
 Table 88. AstraZeneca Anti-VEGF Therapy for Cancer Product
 Table 89. AstraZeneca Revenue in Anti-VEGF Therapy for Cancer Business (2019-2024) & (US$ Million)
 Table 90. AstraZeneca Recent Development
 Table 91. Exelixis Company Details
 Table 92. Exelixis Business Overview
 Table 93. Exelixis Anti-VEGF Therapy for Cancer Product
 Table 94. Exelixis Revenue in Anti-VEGF Therapy for Cancer Business (2019-2024) & (US$ Million)
 Table 95. Exelixis Recent Development
 Table 96. Boehringer Ingelheim Company Details
 Table 97. Boehringer Ingelheim Business Overview
 Table 98. Boehringer Ingelheim Anti-VEGF Therapy for Cancer Product
 Table 99. Boehringer Ingelheim Revenue in Anti-VEGF Therapy for Cancer Business (2019-2024) & (US$ Million)
 Table 100. Boehringer Ingelheim Recent Development
 Table 101. Eisai Company Details
 Table 102. Eisai Business Overview
 Table 103. Eisai Anti-VEGF Therapy for Cancer Product
 Table 104. Eisai Revenue in Anti-VEGF Therapy for Cancer Business (2019-2024) & (US$ Million)
 Table 105. Eisai Recent Development
 Table 106. Janssen Biotech Company Details
 Table 107. Janssen Biotech Business Overview
 Table 108. Janssen Biotech Anti-VEGF Therapy for Cancer Product
 Table 109. Janssen Biotech Revenue in Anti-VEGF Therapy for Cancer Business (2019-2024) & (US$ Million)
 Table 110. Janssen Biotech Recent Development
 Table 111. Research Programs/Design for This Report
 Table 112. Key Data Information from Secondary Sources
 Table 113. Key Data Information from Primary Sources
 Table 114. Authors List of This Report


List of Figures
 Figure 1. Anti-VEGF Therapy for Cancer Picture
 Figure 2. Global Anti-VEGF Therapy for Cancer Market Size Comparison by Type (2024-2030) & (US$ Million)
 Figure 3. Global Anti-VEGF Therapy for Cancer Market Share by Type: 2023 VS 2030
 Figure 4. VEGF Inhibitors Features
 Figure 5. VEGFR Inhibitors Features
 Figure 6. Global Anti-VEGF Therapy for Cancer Market Size by Application (2024-2030) & (US$ Million)
 Figure 7. Global Anti-VEGF Therapy for Cancer Market Share by Application: 2023 VS 2030
 Figure 8. Colorectal Cancer Case Studies
 Figure 9. Non-small Cell Lung Cancer Case Studies
 Figure 10. Renal Cell Carcinoma Case Studies
 Figure 11. Cervical Cancer Case Studies
 Figure 12. Medullary Thyroid Cancer Case Studies
 Figure 13. Other Case Studies
 Figure 14. Anti-VEGF Therapy for Cancer Report Years Considered
 Figure 15. Global Anti-VEGF Therapy for Cancer Market Size (US$ Million), Year-over-Year: 2019-2030
 Figure 16. Global Anti-VEGF Therapy for Cancer Market Size, (US$ Million), 2019 VS 2023 VS 2030
 Figure 17. Global Anti-VEGF Therapy for Cancer Market Share by Region: 2023 VS 2030
 Figure 18. Global Anti-VEGF Therapy for Cancer Market Share by Players in 2023
 Figure 19. Global Top Anti-VEGF Therapy for Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-VEGF Therapy for Cancer as of 2023)
 Figure 20. The Top 10 and 5 Players Market Share by Anti-VEGF Therapy for Cancer Revenue in 2023
 Figure 21. North America Anti-VEGF Therapy for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 22. North America Anti-VEGF Therapy for Cancer Market Share by Country (2019-2030)
 Figure 23. United States Anti-VEGF Therapy for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 24. Canada Anti-VEGF Therapy for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 25. Europe Anti-VEGF Therapy for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 26. Europe Anti-VEGF Therapy for Cancer Market Share by Country (2019-2030)
 Figure 27. Germany Anti-VEGF Therapy for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 28. France Anti-VEGF Therapy for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 29. U.K. Anti-VEGF Therapy for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 30. Italy Anti-VEGF Therapy for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 31. Russia Anti-VEGF Therapy for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 32. Nordic Countries Anti-VEGF Therapy for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 33. Asia-Pacific Anti-VEGF Therapy for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 34. Asia-Pacific Anti-VEGF Therapy for Cancer Market Share by Region (2019-2030)
 Figure 35. China Anti-VEGF Therapy for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 36. Japan Anti-VEGF Therapy for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 37. South Korea Anti-VEGF Therapy for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 38. Southeast Asia Anti-VEGF Therapy for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 39. India Anti-VEGF Therapy for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 40. Australia Anti-VEGF Therapy for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 41. Latin America Anti-VEGF Therapy for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 42. Latin America Anti-VEGF Therapy for Cancer Market Share by Country (2019-2030)
 Figure 43. Mexico Anti-VEGF Therapy for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 44. Brazil Anti-VEGF Therapy for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 45. Middle East & Africa Anti-VEGF Therapy for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 46. Middle East & Africa Anti-VEGF Therapy for Cancer Market Share by Country (2019-2030)
 Figure 47. Turkey Anti-VEGF Therapy for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 48. Saudi Arabia Anti-VEGF Therapy for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 49. UAE Anti-VEGF Therapy for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 50. Sanofi Revenue Growth Rate in Anti-VEGF Therapy for Cancer Business (2019-2024)
 Figure 51. Eli Lilly Revenue Growth Rate in Anti-VEGF Therapy for Cancer Business (2019-2024)
 Figure 52. Roche Revenue Growth Rate in Anti-VEGF Therapy for Cancer Business (2019-2024)
 Figure 53. Bayer Revenue Growth Rate in Anti-VEGF Therapy for Cancer Business (2019-2024)
 Figure 54. Pfizer Revenue Growth Rate in Anti-VEGF Therapy for Cancer Business (2019-2024)
 Figure 55. Jiangsu Hengrui Pharmaceuticals Revenue Growth Rate in Anti-VEGF Therapy for Cancer Business (2019-2024)
 Figure 56. Chia Tai Tianqing Revenue Growth Rate in Anti-VEGF Therapy for Cancer Business (2019-2024)
 Figure 57. Novartis Revenue Growth Rate in Anti-VEGF Therapy for Cancer Business (2019-2024)
 Figure 58. AstraZeneca Revenue Growth Rate in Anti-VEGF Therapy for Cancer Business (2019-2024)
 Figure 59. Exelixis Revenue Growth Rate in Anti-VEGF Therapy for Cancer Business (2019-2024)
 Figure 60. Boehringer Ingelheim Revenue Growth Rate in Anti-VEGF Therapy for Cancer Business (2019-2024)
 Figure 61. Eisai Revenue Growth Rate in Anti-VEGF Therapy for Cancer Business (2019-2024)
 Figure 62. Janssen Biotech Revenue Growth Rate in Anti-VEGF Therapy for Cancer Business (2019-2024)
 Figure 63. Bottom-up and Top-down Approaches for This Report
 Figure 64. Data Triangulation
 Figure 65. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Lukasiewicz Research Network

RELATED REPORTS

Global Fixation Device for Radiotherapy Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-4H16852
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Group A Streptococcus for Injection Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-37K16619
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Boron Neutron Capture Therapy System Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-30U16301
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Radioactive Glass Microsphere Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-2G16953
Thu Sep 25 00:00:00 UTC 2025

Add to Cart